Oppenheimer analyst Leland Gershell upgraded Ascendis Pharma (NASDAQ: ASND) from Perform to Outperform with a price target of $180.00.The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments Hot Upgrades Upgrades

Ascendis Pharma (ASND) PT Lowered to $157 at TD CowenSeptember 4, 2024 8:36 AM Goldman Sachs Reiterates Buy Rating on Royalty Pharma (RPRX)September 4, 2024 7:44 AM Ascendis Pharma (ASND) PT Lowered to $165 at JPMorganSeptember 4, 2024 7:21 AM Ascendis Pharma (ASND) PT Lowered to $264 at Wells FargoSeptember 4, 2024 6:23 AM Form S-8 Ascendis Pharma A/S September 4, 2024 6:03 AM Ascendis Pharma (ASND) PT Lowered to $174 at JefferiesSeptember 4, 2024 5:18 AM Ascendis Pharma (ASND) PT Lowered to $180 at Goldman SachsSeptember 4, 2024 5:06 AM Ascendis Pharma (ASND) PT Lowered to $178 at CitiSeptember 4, 2024 4:57 AM Ascendis Pharma (ASND) Misses Q2 EPS by 55c; cuts Skytrofa revenue outlookSeptember 3, 2024 5:15 PM Form 6-K Ascendis Pharma A/S For: Sep 03September 3, 2024 5:15 PM Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding AgreementSeptember 3, 2024 5:14 PM Form 6-K Ascendis Pharma A/S For: Sep 03September 3, 2024 5:12 PM Form 6-K Ascendis Pharma A/S For: Jun 30September 3, 2024 5:11 PM Ascendis Pharma (ASND) and Royalty Pharma (RPRX) Enter $150M Royalty Funding AgreementSeptember 3, 2024 5:07 PM Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding AgreementSeptember 3, 2024 5:06 PM Ascendis Pharma Reports Second Quarter 2024 Financial ResultsSeptember 3, 2024 5:04 PM